Global X S&P Biotech ETF - Managed Fund

Fund Objective

The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Fund Strategy

The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Fund Performance Comparison

Relative Fund Performance vs {{ fund.benchmark.peers.peerCount }} peers using {{ fund.benchmark.name }} as their benchmark.

{{ fund.name }}

Peers

Benchmark ({{ fund.benchmark.name }})

{{ fund.model.name }}

The performance of the peers is calculated as the total of the performance for each time period for all the funds in the peer group, divided by the number of funds in the peer group.

Fund performance

	1M	3M	6M	1Y p.a.	2Y p.a.	3Y p.a.	5Y p.a.	10Y p.a.
Total return	13.95%	29.43%	32.57%	15.96%	27.88%	10.04%	1.25%	-%
Growth return	13.95%	29.43%	32.57%	15.96%	-%	10.04%	-0.7%	-%
Income return	0%	0%	0%	0%	-%	0%	1.95%	-%
Market index (MSCI World Ex Australia NR AUD)
Total return	3.32%	6.34%	18.35%	22.32%	25.76%	20.9%	17.3%	12.82%

As at 31 Oct 2025. Returns for periods greater than 1 year are annualised. All figures are percentages.

General Information

Fund Details

Type	Description
Fund Name	Global X S&P Biotech ETF
Responsible Entity	ANZ ETFS Management (AUS) Ltd
APIR Code
Sector/Asset Class	Equity World Other
Morningstar Rating	Not Rated
Legal Structure	Investment Fund
Fund Inception	8 Nov 2018
Fund Size	$38.72 million (as at 19 Nov 2025)
Entry Price	$42.5 (as at 30 Aug 2023)
Exit Price	$40 (as at 30 Aug 2023)
Fund Status	Open

Offer information

Type	Description
MER	0.45% (as at 22 Sep 2025)
Indirect Cost Ratio (ICR)	0.45% (as at 30 Jun 2025)
Performance fee (not included in ICR)	0
Minimum initial investment	$500.00

Top 10 holdings (as at 18 Nov 2025)

Holding (as at 18 Nov 2025)	Type	% of Portfolio
Revolution Medicines Inc Ordinary Shares	Equity	2.50%
Login now to view the complete list of holdings.

Your guide to next steps

Dealing with a struggling fund? What to Do and Look For

How to Assess your Managed Fund: And How to Choose the Next One

Your managed fund switching checklist. Is fear of capital gains tax holding you back?

The Great Investment Fee Scam is hiding in plain sight. And it's ripping us all off.

Guide to tidying up your Portfolio Manager holdings

FAQs about the Global X S&P Biotech ETF

What is the objective of the Global X S&P Biotech ETF managed fund?

The objective of the Global X S&P Biotech ETF managed fund is The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

What is the strategy for the Global X S&P Biotech ETF managed fund?

The strategy of the Global X S&P Biotech ETF managed fund is The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

What is the APIR code of the Global X S&P Biotech ETF managed fund?

The APIR code of the Global X S&P Biotech ETF managed fund is .

What was Global X S&P Biotech ETF’s total return last month?

Global X S&P Biotech ETF’s total return last month was 13.95%. This was made up of a growth return of 13.95% and an income return of 0%. These returns were calculated as at 31 Oct 2025.

What was Global X S&P Biotech ETF’s total return for the last three months?

Global X S&P Biotech ETF’s total return for the last three months was 29.43%. This was made up of a growth return of 29.43% and an income return of 0%%. These returns were calculated as at 31 Oct 2025.

What is Global X S&P Biotech ETF’s one-year total return?

Global X S&P Biotech ETF’s one-year total return is 15.96%. This was made up of a growth return of 15.96% and an income return of 0%. These returns were calculated as at 31 Oct 2025.

What is Global X S&P Biotech ETF’s three-year total return?

Global X S&P Biotech ETF’s one-year total return is 10.04%. This was made up of a growth return of 10.04% and an income return of 0%. These returns were calculated as at 31 Oct 2025.

What is the asset allocation of the Global X S&P Biotech ETF managed fund?

The asset allocation of the Global X S&P Biotech ETF managed fund is :

International Equities: 100%

Australian Equities: 0%

Cash: 0%

Property & Infrastructure: 0%

Fixed Interest: 0%

Alternatives: 0%

Who is the responsible Entity of the Global X S&P Biotech ETF managed fund?

The Responsible Entity for the Global X S&P Biotech ETF managed fund is ANZ ETFS Management (AUS) Ltd.

What sector/asset class does the Global X S&P Biotech ETF managed fund belong to?

The Global X S&P Biotech ETF managed fund belongs to the Equity World Other sector/asset class.

What is the size of the Global X S&P Biotech ETF managed fund?

As at 19 Nov 2025, the size of the Global X S&P Biotech ETF managed fund was $38.72 million.

What is the inception date of the Global X S&P Biotech ETF managed fund?

The Global X S&P Biotech ETF managed fund has an inception date of 8 Nov 2018.

What is the current entry price of the Global X S&P Biotech ETF managed fund?

The current entry price of the Global X S&P Biotech ETF managed fund is $42.5 per unit and the current exit price is $40 per unit (as at 30 Aug 2023).

What is the current exit price of the Global X S&P Biotech ETF managed fund?

The current exit price of the Global X S&P Biotech ETF managed fund is $40 per unit and the current entry price is $42.5 per unit (as at 30 Aug 2023).

What is the minimum investment amount for the Global X S&P Biotech ETF managed fund?

The minimum initial investment amount for the Global X S&P Biotech ETF managed fund is $500.

Fund data sourced from Morningstar. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only. Whilst every care has been taken in producing these numbers, neither Morningstar nor InvestSMART can make any guarantees around the complete accuracy of these figures. Should you decide to change investments, please read all relevant disclosure documents including the Product Disclosure Statements and if required, you may consider speaking to a financial professional for further guidance. A tax event may be realised as a result of switching investments. Past performance is not a reliable indicator of future performance.

What our members say about us